NANO.PA stock jumped 18.74% intraday to €27.25 on 02 Mar 2026 after heavy buying pushed volume to 436,333 shares. The move followed a higher open at €25.00 and a day high of €28.35, as traders reacted to clinical-development momentum and repositioning in biotechnology names across EURONEXT. We examine why Nanobiotix S.A. (NANO.PA) is leading top-gainers today, link the price action to fundamentals and technicals, and set short- and medium-term scenarios for investors in Europe.

Intraday price action and volume drivers for NANO.PA stock

NANO.PA stock gained sharply from a previous close of €22.95 to trade at €27.25 intraday, with a day range between €24.25 and €28.35. Volume at 436,333 shares was 3.29x the average daily volume of 148,999, signalling conviction behind the rally. Market participants cited clinical updates and sector rotation into healthcare biotechs as drivers, and EURONEXT order flow showed sustained buying into the mid-session high.

Technical snapshot: momentum and overbought signals

Technicals show short-term strength and overbought conditions for NANO.PA stock. The RSI is 77.59, MACD histogram is positive at 0.34, and ADX at 32.55 indicates a strong trend. Bollinger Bands middle sits near €20.81 and the upper band at €24.86, underlining the recent volatility expansion. Traders should note the overbought MFI of 81.97, which increases the chance of a pullback or consolidation after sharp intraday gains.

Fundamentals and valuation context for Nanobiotix S.A.

Nanobiotix S.A. (NANO.PA) is a clinical-stage biotech in Healthcare on EURONEXT with a market cap of €1,248,177,736.00 and shares outstanding 48,378,982. The company reports EPS of -1.09 and a trailing PE of -23.67, reflecting ongoing development-stage losses. Price-to-sales and price-to-book ratios are extreme at 217.45 and -17.74 respectively, so current pricing is driven by future potential rather than current revenue.

Meyka AI grade and analyst-style assessment for NANO.PA stock

Meyka AI rates NANO.PA with a score of 73.79 out of 100 — Grade B+, Suggestion: BUY. This grade factors in S&P 500 and sector comparison, financial growth, key metrics, forecasts and analyst consensus. The internal grade highlights growth potential from clinical readouts but also rates capital structure and negative cash flow as risks. These grades are informational and not personalised investment advice.

Catalysts, risks and sector comparison affecting NANO.PA stock

Near-term catalysts include upcoming trial data and regulatory updates, with the next earnings announcement scheduled for 2026-03-31. Key risks are continued negative EPS (-1.09), a weak current ratio of 0.63, and high valuation multiples versus European biotech peers. The Healthcare sector in Europe has been modestly positive year-to-date, and rotation into selected high-beta biotech names can amplify moves in NANO.PA.

Price forecasts and trading setups for short and medium term

Meyka AI’s forecast model projects a quarterly target of €27.44, a 12-month target of €25.46, and a 3-year target of €46.20 for NANO.PA stock. Compared with the intraday price of €27.25, the quarterly target implies +0.70% upside and the 12-month target implies -6.58% downside. Short-term traders may use intraday support near €24.25 and resistance near €28.35, while longer-term investors should weigh runway for trials and cash burn.

Final Thoughts

NANO.PA stock’s intraday jump to €27.25 on 02 Mar 2026 reflects heavy buying, clinical-development optimism, and a sector-wide tilt toward high-beta biotech names on EURONEXT. Technical indicators show strong momentum but clear overbought signals that raise the probability of a near-term pullback. Fundamentals remain typical of a clinical-stage biotech: negative EPS (-1.09), tight liquidity with a current ratio of 0.63, and valuation metrics that price in future success rather than present sales. Meyka AI’s forecast model projects a quarterly level of €27.44 (+0.70% vs current) and a 12-month level of €25.46 (-6.58% vs current), while a 3-year model target of €46.20 implies larger upside for successful clinical milestones. Meyka AI, an AI-powered market analysis platform, flags both the opportunity from potential trial wins and the liquidity and valuation risks. Investors should position size carefully, use stop levels around intraday support, and monitor upcoming trial and earnings dates for clearer directional cues. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.